Chaolin Huang and colleagues1 have highlighted the putative renal consequences of COVID-19 at 6 months from discharge. A decreased estimated glomerular filtration rate (eGFR) was defined as less than 90 mL/min per 1·73 m2 and was observed in 35% of participants during follow-up. The term decreased eGFR is ambiguous. According to the mean age of the cohort, chronic kidney disease should be defined as an eGFR of less than 60 mL/min per 1·73 m2.2 The usual prevalence of eGFR less than 90 mL/min per 1·73 m2 in the Chinese general population of similar ages to those in Huang and colleagues' cohort ranges between 35% and 50%.3, 4 In other words, the prevalence of eGFR of less than 90 mL/min per 1·73 m2 in COVID-19 survivors might not differ from the general population. Furthermore, the majority of patients with eGFR less than 90 mL/min per 1·73 m2 during follow-up did not show acute kidney injury during the acute phase, which suggests that the eGFR of these patients was already less than 90 mL/min per 1·73 m2 before COVID-19. Therefore, the prevalence of patients with eGFR less than 60 mL/min per 1·73 m2 at 6 months from discharge is required to factually assess the long-term effect of COVID-19 on renal function. The pathological relevance of an eGFR between 60 and 90 mL/min per 1·73 m2 is questionable in the absence of proteinuria.2 Proteinuria has been frequently described in patients with COVID-19. Our follow-up observations suggest a spontaneous remission within a few weeks after discharge.5 The available data of Huang and colleagues do not support their alarming conclusions about the poor renal prognosis at 6 months after COVID-19.
Acknowledgments
We declare no competing interests.
References
- 1.Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220–232. doi: 10.1016/S0140-6736(20)32656-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Delanaye P, Jager KJ, Bökenkamp A, et al. CKD: a call for an age-adapted definition. J Am Soc Nephrol. 2019;30:1785–1805. doi: 10.1681/ASN.2019030238. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379:815–822. doi: 10.1016/S0140-6736(12)60033-6. [DOI] [PubMed] [Google Scholar]
- 4.Wang S, Chen R, Liu Q, Shu Z, Zhan S, Li L. Prevalence, awareness and treatment of chronic kidney disease among middle-aged and elderly: The China Health and Retirement Longitudinal Study. Nephrology (Carlton) 2015;20:474–484. doi: 10.1111/nep.12449. [DOI] [PubMed] [Google Scholar]
- 5.Huart J, Bouquegneau A, Lutteri L, et al. Proteinuria in COVID-19: prevalence, characterization and prognostic role. J Nephrol. 2021;34:355–364. doi: 10.1007/s40620-020-00931-w. [DOI] [PMC free article] [PubMed] [Google Scholar]